255 related articles for article (PubMed ID: 35579752)
1. Anticoagulation and bleeding in the cancer patient.
Escobar A; Salem AM; Dickson K; Johnson TN; Burk KJ; Bashoura L; Faiz SA
Support Care Cancer; 2022 Oct; 30(10):8547-8557. PubMed ID: 35579752
[TBL] [Abstract][Full Text] [Related]
2. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.
Dhakal P; Rayamajhi S; Verma V; Gundabolu K; Bhatt VR
Clin Appl Thromb Hemost; 2017 Jul; 23(5):410-415. PubMed ID: 27789605
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
5. When and How to Use Reversal Agents for Direct Oral Anticoagulants?
Gómez-Outes A; Suárez-Gea ML; Lecumberri R
Curr Cardiol Rep; 2023 May; 25(5):371-380. PubMed ID: 36976497
[TBL] [Abstract][Full Text] [Related]
6. Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal.
Karcioglu O; Zengin S; Ozkaya B; Ersan E; Yilmaz S; Afacan G; Abuska D; Hosseinzadeh M; Yeniocak S
Cardiovasc Hematol Agents Med Chem; 2022; 20(2):103-113. PubMed ID: 34521332
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants (DOAC) - Management of emergency situations.
Lindhoff-Last E
Hamostaseologie; 2017; 37(4):257-266. PubMed ID: 29582928
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
Levy JH
Am J Med; 2016 Nov; 129(11S):S47-S53. PubMed ID: 27569675
[TBL] [Abstract][Full Text] [Related]
9. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
Milling TJ; Ziebell CM
Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
[TBL] [Abstract][Full Text] [Related]
10. Reversal agents for oral anticoagulant-associated major or life-threatening bleeding.
Moia M; Squizzato A
Intern Emerg Med; 2019 Nov; 14(8):1233-1239. PubMed ID: 31446606
[TBL] [Abstract][Full Text] [Related]
11. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
Tummala R; Kavtaradze A; Gupta A; Ghosh RK
Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
[TBL] [Abstract][Full Text] [Related]
12. Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies.
Raimondi P; Hylek EM; Aronis KN
Curr Pharm Des; 2017; 23(9):1406-1423. PubMed ID: 27917717
[TBL] [Abstract][Full Text] [Related]
13. Present Knowledge on Direct Oral Anticoagulant and Novel Oral Anti Coagulants and Their Specific Antidotes: A Comprehensive Review Article.
Biswas S; Bahar Y; Bahar AR; Safiriyu I; Mathai SV; Hajra A; Gupta R; Aronow WS
Curr Probl Cardiol; 2023 Feb; 48(2):101483. PubMed ID: 36336118
[TBL] [Abstract][Full Text] [Related]
14. Reversal strategies in patients treated with direct oral anticoagulants.
Gressenberger P
Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
[No Abstract] [Full Text] [Related]
15. Reversal of direct oral anticoagulants.
Almegren M
Vasc Health Risk Manag; 2017; 13():287-292. PubMed ID: 28769570
[TBL] [Abstract][Full Text] [Related]
16. Direct Oral Anticoagulant for the Treatment of VTE in Cancer Patients: A Systematic Review and Meta-analysis.
Dong S; Zhang Y; Li Y; Li Y; Miao Y; Zhao R; Zhai S
Ann Pharmacother; 2021 Apr; 55(4):430-439. PubMed ID: 32938202
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
18. [Reversal agents for severe bleeding associated with direct oral anticoagulants].
Giubilato S; Lucà F; Di Fusco SA; Amico F; Colivicchi F; Gulizia MM
G Ital Cardiol (Rome); 2022 Oct; 23(10):734-745. PubMed ID: 36169124
[TBL] [Abstract][Full Text] [Related]
19. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer.
Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T
J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316
[TBL] [Abstract][Full Text] [Related]
20. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
Patel A; Williams H; Baer MR; Zimrin AB; Law JY
Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
